• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Penumbra Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/30/25 4:13:28 PM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email
    pen-20250528
    0001321732FALSE12/3100013217322022-06-012022-06-0100013217322025-04-012025-06-30

    __________________________________________________________________________________________________________________________

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _______________________________________________________________________________________________________________________________

    FORM 8-K 
    _______________________________________________________________________________________________________________________________

    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

    May 28, 2025
    Date of Report (Date of earliest event reported) 
    _______________________________________________________________________________________________________________________________

    Penumbra, Inc.
    (Exact name of registrant as specified in its charter)
    _______________________________________________________________________________________________________________________________
    Delaware001-3755705-0605598
    (State or other jurisdiction of incorporation or organization)(Commission File No.)(I.R.S. employer identification number)
    One Penumbra Place
    Alameda, CA 94502
    (Address of principal executive offices, including zip code)
     
    (510) 748-3200
    (Registrant’s telephone number, including area code) 
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: 
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange on which registered
    Common Stock, Par value $0.001 per sharePENThe New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





    Item 5.03.Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
     
    On May 28, 2025, Penumbra, Inc. (“Penumbra” or the “Company”) filed an Amended and Restated Certificate of Incorporation (the “Amended and Restated Charter”) with the Secretary of State of the State of Delaware, which became effective upon such filing. In addition, on May 28, 2025, following stockholder approval of the Amended and Restated Charter, as described in Item 5.07 below, an amendment and restatement of the Company’s Second Amended and Restated Bylaws became effective (the “Third Amended and Restated Bylaws”). As further described in Penumbra’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 16, 2025 (the “Proxy Statement”), the Amended and Restated Charter and the Third Amended and Restated Bylaws have two effects: (i) to phase in the declassification of Penumbra’s Board of Directors (the “Board”) over a three-year period to allow the Company’s stockholders to vote on the election of directors generally on an annual basis, rather than on a staggered basis (the “Declassification Amendment”), and (ii) to replace the provisions in Penumbra’s Restated Certificate of Incorporation and Second Amended and Restated Bylaws (collectively, the “Organizational Documents”) that require the affirmative vote of sixty-six and two-thirds percent (66 2/3%) of Penumbra’s voting stock (the “Supermajority Voting Requirement”) for stockholders to take certain actions with a majority voting standard for such actions (the “Supermajority Amendment”).

    As a result of the Declassification Amendment, each director who stands for election or re-election at and after the 2026 annual meeting of stockholders following the completion of such director’s then-current three-year term will be elected for a one-year term, expiring at the next year’s annual stockholder meeting, and the Board structure will be completely declassified by the 2028 annual meeting of stockholders. Commencing with the 2028 annual meeting of stockholders, Penumbra's directors will no longer be divided into classes.

    As a result of the Supermajority Amendment, the Supermajority Voting Requirement is eliminated and provisions of the Organizational Documents that would have required supermajority stockholder approval will instead require approval of the holders of not less than a majority of the total voting power of all outstanding securities of the Company generally entitled to vote in the election of directors.

    The foregoing description of the Amended and Restated Charter and the Third Amended and Restated Bylaws is qualified in its entirety by reference to (1) the Amended and Restated Certificate of Incorporation filed as Exhibit 3.1 hereto, and (2) the Third Amended and Restated Bylaws filed as Exhibit 3.2 hereto, each of which is incorporated herein by reference.

    Item 5.07.Submission of Matters to a Vote of Security Holders.

    (a)Penumbra held its Annual Meeting of Stockholders on May 28, 2025 (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended. At the close of business on March 31, 2025, the record date for the Annual Meeting, there were 38,683,650 shares of the Company’s common stock, par value $0.001 per share, outstanding and entitled to vote, and 35,704,492 of such shares were voted in person or by proxy at the Annual Meeting on the proposals described below.

    (b)At the Annual Meeting, Penumbra’s stockholders voted on the following five proposals, each of which is described in more detail in the Proxy Statement. The number of votes cast with respect to each proposal was as indicated below:
    1)
    Election of Class I Directors. The following nominees were elected to serve as Class I directors until the Company’s 2028 annual meeting of stockholders and until their respective successors are duly elected and qualified, or, if sooner, until the director’s death, resignation or removal, based on the following results of voting:
    NomineeVotes ForVotes WithheldBroker Non-Votes
    Janet Leeds29,898,5051,905,3273,900,660
    Thomas Wilder27,191,6724,612,1603,900,660
    2)
    Ratification of Selection of Independent Registered Public Accounting Firm. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Penumbra for the fiscal year ending December 31, 2025 was ratified based on the following results of voting:
    Votes ForVotes AgainstAbstentionsBroker Non-Votes
    35,592,55399,08212,857N/A
    3)
    Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers. The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following results of voting:



    Votes ForVotes AgainstAbstentionsBroker Non-Votes
    31,081,357707,81014,6653,900,660
    4)
    Approval of an amendment to the Company’s Restated Certificate of Incorporation (the “Charter”) to phase in the declassification of the Company’s Board of Directors. The amendment to the Charter was approved based on the following results of voting:
    Votes ForVotes AgainstAbstentionsBroker Non-Votes
    31,773,32825,6234,8813,900,660
    5)
    Approval of an amendment to the Charter to eliminate the supermajority voting requirements. The amendment to the Charter was approved based on the following results of voting:
    Votes ForVotes AgainstAbstentionsBroker Non-Votes
    31,755,83742,9465,0493,900,660

    Item 9.01.Financial Statements and Exhibits.

    (d) Exhibits.
    Exhibit Number Description
    3.1
    Amended and Restated Certificate of Incorporation of Penumbra, Inc.
    3.2
    Third Amended and Restated Bylaws of Penumbra, Inc.
    104Cover Page Interactive Data File (formatted as Inline Extensible Business Reporting Language).



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
           
        PENUMBRA, INC.
        
    Date: May 30, 2025   By: /s/ Johanna Roberts
          Johanna Roberts
          Executive Vice President, General Counsel and Secretary


    Get the next $PEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    9/18/2024$238.00Buy
    Stifel
    9/3/2024$263.00Outperform
    Leerink Partners
    7/31/2024$289.00 → $150.00Overweight → Equal Weight
    Wells Fargo
    7/31/2024$165.00 → $178.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PEN
    SEC Filings

    See more
    • SEC Form SD filed by Penumbra Inc.

      SD - Penumbra Inc (0001321732) (Filer)

      5/30/25 4:20:01 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Penumbra Inc (0001321732) (Filer)

      5/30/25 4:13:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Penumbra Inc.

      144 - Penumbra Inc (0001321732) (Subject)

      5/15/25 4:03:13 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Gen. Counsel & Secretary Roberts Johanna sold $151,622 worth of shares (600 units at $252.70), decreasing direct ownership by 0.90% to 66,057 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      7/3/25 7:54:20 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • EVP, Gen. Counsel & Secretary Roberts Johanna exercised 1,943 shares at a strike of $22.04, increasing direct ownership by 3% to 66,657 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      6/27/25 8:04:23 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $4,026,589 worth of shares (15,890 units at $253.40), increasing direct ownership by 11% to 122,441 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      6/27/25 8:02:38 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

      Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

      10/10/24 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

      SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

      10/24/22 8:30:00 AM ET
      $BLZE
      $GSIT
      $PEN
      Computer Software: Prepackaged Software
      Technology
      Semiconductors
      Medical/Dental Instruments

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/14/24 1:22:36 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/12/24 12:53:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Penumbra Inc.

      SC 13G - Penumbra Inc (0001321732) (Subject)

      2/14/24 10:03:02 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

      ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "

      7/1/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

      STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolism ALAMEDA, Calif., June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for the treatment of acute

      6/16/25 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

      ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii. "We've engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings," said Shruthi Naraya

      6/5/25 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Penumbra with a new price target

      BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

      3/14/25 7:46:38 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on Penumbra with a new price target

      UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00

      1/21/25 8:26:37 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Penumbra with a new price target

      Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00

      12/17/24 7:54:12 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Financials

    Live finance-specific insights

    See more
    • Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

      ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "

      7/1/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care